First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment

Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I st...

Description complète

Détails bibliographiques

Auteurs principaux:	Daria V. Vasina, Denis A. Kleymenov, Victor A. Manuylov, Elena P. Mazunina, Egor Yu. Koptev, Elena A. Tukhovskaya, Arkady N. Murashev, Alexander L. Gintsburg, Vladimir A. Gushchin, Artem P. Tkachuk
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2019-11-01
Collection:	Vaccines
Sujets:	tuberculosis subunit vaccine bcg booster clinical trials safety and immunogenicity
Accès en ligne:	https://www.mdpi.com/2076-393X/7/4/166
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!